Home/Filings/4/0001654954-19-010955
4//SEC Filing

Drexler Ryan Charles 4

Accession 0001654954-19-010955

CIK 0001415684other

Filed

Sep 19, 8:00 PM ET

Accepted

Sep 20, 6:10 AM ET

Size

10.2 KB

Accession

0001654954-19-010955

Insider Transaction Report

Form 4
Period: 2018-01-05
Drexler Ryan Charles
Director10% Owner
Transactions
  • Other

    Common Stock

    2018-01-05$0.65/sh+81,113$52,723663,037 total
  • Conversion

    Common Stock

    2019-09-16$1.11/sh+16,216,216$18,000,00016,879,253 total
  • Conversion

    Convertible Promissory Note (right to buy)

    2019-09-1600 total
    Exercise: $1.11Exp: 2019-12-31Common Stock (16,216,216 underlying)
Holdings
  • Common Stock

    (indirect: See footnote)
    1,499,408
Footnotes (4)
  • [F1]The Reporting Person was issued shares of common stock in lieu of cash interest in accordance with the terms of the Note (as defined below).
  • [F2]The Reporting Person was issued shares of common stock upon his partial conversion, at a conversion price of $1.11 per share, of $18,000,000 of the amount outstanding under an Amended and Restated Convertible Secured Promissory Note, dated as of November 8, 2017 (the "Note"), issued by the Issuer to the Reporting Person. Following the partial conversion, there remained $1,262,910.15 of principal amount outstanding under the note and no outstanding interest as of such date. The Note bears interest at the rate of 12% per annum, with interest payments due on the last day of each quarter.
  • [F3]Represents shares of common stock held by Consac LLC ("Consac").The Reporting Person is the Chief Executive Officer of Consac and may be deemed to be the indirect beneficial owner (as that term is defined under Rule 13d-3 of the Securities Exchange Act) of the common stock that Consac beneficially owns. The Reporting Person has the power to direct the voting and disposition of the Issuer's common stock that Consac beneficially owns.
  • [F4]The Reporting Person may convert the outstanding principal and accrued interest under the Note into shares of common stock at any time at a conversion price of $1.11 per share.

Issuer

MusclePharm Corp

CIK 0001415684

Entity typeother

Related Parties

1
  • filerCIK 0001648033

Filing Metadata

Form type
4
Filed
Sep 19, 8:00 PM ET
Accepted
Sep 20, 6:10 AM ET
Size
10.2 KB